一项多中心回顾性研究预测急性缺氧呼吸衰竭患者早期无创通气失败

IF 2.3 4区 医学 Q3 RESPIRATORY SYSTEM
Xiaoyi Liu, Hui Liu, Lijuan Chen, Xiangde Zheng, Hui Ran, Lili Chen, Rui Zhou, Yufeng Wang
{"title":"一项多中心回顾性研究预测急性缺氧呼吸衰竭患者早期无创通气失败","authors":"Xiaoyi Liu,&nbsp;Hui Liu,&nbsp;Lijuan Chen,&nbsp;Xiangde Zheng,&nbsp;Hui Ran,&nbsp;Lili Chen,&nbsp;Rui Zhou,&nbsp;Yufeng Wang","doi":"10.1111/crj.70098","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Volume OXygenation (VOX) index has good efficacy in predicting the failure of high-flow nasal cannula therapy. However, its predictive value for treatment failure in patients receiving noninvasive ventilation (NIV) remains uncertain.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Patients who underwent early NIV treatment were grouped based on their 2-h NIV VOX Youden index. The low-risk group consisted of patients with a VOX value &gt; 20.45 (<i>n</i> = 188), while the high-risk group included those with a VOX value ≤ 20.45 (<i>n</i> = 200). Baseline data and arterial blood gas values were collected at 2, 12, and 24 h after NIV initiation.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared to the low-risk group, the high-risk group exhibited higher SOFA scores, respiratory rates, and heart rates, along with a lower oxygenation index (P/F) (all <i>p</i> &lt; 0.05). Following NIV treatment, the low-risk group showed a more significant increase in P/F values at 2 h, 12 h, and 24 h after NIV initiation. The low-risk group showed a lower VT and MV (minute ventilation volume) at 2 h, 12 h, and 24 h of NIV (<i>p</i> &lt; 0.05). Moreover, the low-risk group had a lower intubation rate (7.98% vs. 77%, <i>p</i> &lt; 0.05) and mortality rate (4.79% vs. 17.5%, <i>p</i> &lt; 0.05). At 2 h of NIV, the area under the receiver operating characteristic curve for predicting NIV failure using the VOX index was 0.843 (95% CI 0.805–0.882). Using a VOX value threshold of 20.45 to predict NIV failure, the sensitivity was 69.1%, and the specificity was 94.4%. Furthermore, a VOX value ≤ 20.45 was identified as an independent risk factor for tracheal intubation and death.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>VOX index shows promise to serve as an effective evaluation index to predict early NIV efficacy in patients with AHRF; a VOX value &gt; 20.45 after 2 h of NIV treatment can better predict improvements in hypoxia, respiratory drive, and NIV outcomes, guide early tracheal intubation in cases of NIV failure, and have a certain predictive effect on patient outcomes.</p>\n </section>\n </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"19 7","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70098","citationCount":"0","resultStr":"{\"title\":\"A Multicenter Retrospective Study Predicting Early Noninvasive Ventilation Failure in Patients With Acute Hypoxic Respiratory Failure\",\"authors\":\"Xiaoyi Liu,&nbsp;Hui Liu,&nbsp;Lijuan Chen,&nbsp;Xiangde Zheng,&nbsp;Hui Ran,&nbsp;Lili Chen,&nbsp;Rui Zhou,&nbsp;Yufeng Wang\",\"doi\":\"10.1111/crj.70098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Volume OXygenation (VOX) index has good efficacy in predicting the failure of high-flow nasal cannula therapy. However, its predictive value for treatment failure in patients receiving noninvasive ventilation (NIV) remains uncertain.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Patients who underwent early NIV treatment were grouped based on their 2-h NIV VOX Youden index. The low-risk group consisted of patients with a VOX value &gt; 20.45 (<i>n</i> = 188), while the high-risk group included those with a VOX value ≤ 20.45 (<i>n</i> = 200). Baseline data and arterial blood gas values were collected at 2, 12, and 24 h after NIV initiation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Compared to the low-risk group, the high-risk group exhibited higher SOFA scores, respiratory rates, and heart rates, along with a lower oxygenation index (P/F) (all <i>p</i> &lt; 0.05). Following NIV treatment, the low-risk group showed a more significant increase in P/F values at 2 h, 12 h, and 24 h after NIV initiation. The low-risk group showed a lower VT and MV (minute ventilation volume) at 2 h, 12 h, and 24 h of NIV (<i>p</i> &lt; 0.05). Moreover, the low-risk group had a lower intubation rate (7.98% vs. 77%, <i>p</i> &lt; 0.05) and mortality rate (4.79% vs. 17.5%, <i>p</i> &lt; 0.05). At 2 h of NIV, the area under the receiver operating characteristic curve for predicting NIV failure using the VOX index was 0.843 (95% CI 0.805–0.882). Using a VOX value threshold of 20.45 to predict NIV failure, the sensitivity was 69.1%, and the specificity was 94.4%. Furthermore, a VOX value ≤ 20.45 was identified as an independent risk factor for tracheal intubation and death.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>VOX index shows promise to serve as an effective evaluation index to predict early NIV efficacy in patients with AHRF; a VOX value &gt; 20.45 after 2 h of NIV treatment can better predict improvements in hypoxia, respiratory drive, and NIV outcomes, guide early tracheal intubation in cases of NIV failure, and have a certain predictive effect on patient outcomes.</p>\\n </section>\\n </div>\",\"PeriodicalId\":55247,\"journal\":{\"name\":\"Clinical Respiratory Journal\",\"volume\":\"19 7\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.70098\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Respiratory Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/crj.70098\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Respiratory Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/crj.70098","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景:体积氧合(VOX)指数对预测高流量鼻插管治疗失败有较好的效果。然而,其对无创通气(NIV)患者治疗失败的预测价值仍不确定。方法根据2 h VOX约登指数对早期NIV治疗的患者进行分组。低危组由VOX值为>;20.45 (n = 188),高危组为VOX≤20.45 (n = 200)。基线数据和动脉血气值在NIV启动后2、12和24小时收集。结果与低危组相比,高危组SOFA评分、呼吸频率、心率较高,氧合指数(P/F)较低(P < 0.05)。在NIV治疗后,低危组在NIV开始后2小时、12小时和24小时的P/F值增加更为显著。低危组在NIV的2 h、12 h和24 h的VT和MV(分钟通气量)较低(p < 0.05)。低危组插管率(7.98%比77%,p < 0.05)和死亡率(4.79%比17.5%,p < 0.05)较低。在NIV第2小时,使用VOX指数预测NIV失效的受试者工作特征曲线下面积为0.843 (95% CI 0.805-0.882)。使用20.45的VOX阈值预测NIV失败,敏感性为69.1%,特异性为94.4%。此外,VOX值≤20.45被确定为气管插管和死亡的独立危险因素。结论VOX指数有望作为预测AHRF患者早期NIV疗效的有效评价指标;a VOX值>;20.45 NIV治疗2 h后能较好地预测缺氧、呼吸驱动及NIV结局的改善,指导NIV失败时早期气管插管,对患者结局有一定的预测作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A Multicenter Retrospective Study Predicting Early Noninvasive Ventilation Failure in Patients With Acute Hypoxic Respiratory Failure

A Multicenter Retrospective Study Predicting Early Noninvasive Ventilation Failure in Patients With Acute Hypoxic Respiratory Failure

Background

Volume OXygenation (VOX) index has good efficacy in predicting the failure of high-flow nasal cannula therapy. However, its predictive value for treatment failure in patients receiving noninvasive ventilation (NIV) remains uncertain.

Methods

Patients who underwent early NIV treatment were grouped based on their 2-h NIV VOX Youden index. The low-risk group consisted of patients with a VOX value > 20.45 (n = 188), while the high-risk group included those with a VOX value ≤ 20.45 (n = 200). Baseline data and arterial blood gas values were collected at 2, 12, and 24 h after NIV initiation.

Results

Compared to the low-risk group, the high-risk group exhibited higher SOFA scores, respiratory rates, and heart rates, along with a lower oxygenation index (P/F) (all p < 0.05). Following NIV treatment, the low-risk group showed a more significant increase in P/F values at 2 h, 12 h, and 24 h after NIV initiation. The low-risk group showed a lower VT and MV (minute ventilation volume) at 2 h, 12 h, and 24 h of NIV (p < 0.05). Moreover, the low-risk group had a lower intubation rate (7.98% vs. 77%, p < 0.05) and mortality rate (4.79% vs. 17.5%, p < 0.05). At 2 h of NIV, the area under the receiver operating characteristic curve for predicting NIV failure using the VOX index was 0.843 (95% CI 0.805–0.882). Using a VOX value threshold of 20.45 to predict NIV failure, the sensitivity was 69.1%, and the specificity was 94.4%. Furthermore, a VOX value ≤ 20.45 was identified as an independent risk factor for tracheal intubation and death.

Conclusions

VOX index shows promise to serve as an effective evaluation index to predict early NIV efficacy in patients with AHRF; a VOX value > 20.45 after 2 h of NIV treatment can better predict improvements in hypoxia, respiratory drive, and NIV outcomes, guide early tracheal intubation in cases of NIV failure, and have a certain predictive effect on patient outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Respiratory Journal
Clinical Respiratory Journal 医学-呼吸系统
CiteScore
3.70
自引率
0.00%
发文量
104
审稿时长
>12 weeks
期刊介绍: Overview Effective with the 2016 volume, this journal will be published in an online-only format. Aims and Scope The Clinical Respiratory Journal (CRJ) provides a forum for clinical research in all areas of respiratory medicine from clinical lung disease to basic research relevant to the clinic. We publish original research, review articles, case studies, editorials and book reviews in all areas of clinical lung disease including: Asthma Allergy COPD Non-invasive ventilation Sleep related breathing disorders Interstitial lung diseases Lung cancer Clinical genetics Rhinitis Airway and lung infection Epidemiology Pediatrics CRJ provides a fast-track service for selected Phase II and Phase III trial studies. Keywords Clinical Respiratory Journal, respiratory, pulmonary, medicine, clinical, lung disease, Abstracting and Indexing Information Academic Search (EBSCO Publishing) Academic Search Alumni Edition (EBSCO Publishing) Embase (Elsevier) Health & Medical Collection (ProQuest) Health Research Premium Collection (ProQuest) HEED: Health Economic Evaluations Database (Wiley-Blackwell) Hospital Premium Collection (ProQuest) Journal Citation Reports/Science Edition (Clarivate Analytics) MEDLINE/PubMed (NLM) ProQuest Central (ProQuest) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信